Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus

Eileen M. Broomall, Sonya M. Reynolds, Robert M. Jacobson

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

In October 2009, the Advisory Committee on Immunization Practices (ACIP) approved a newly licensed vaccine, Cervarix®, directed against human papillomavirus (HPV) to prevent cervical cancer. The ACIP also expanded its recommendations against HPV by giving permission to physicians to vaccinate males aged 9 to 26 years with the previously licensed vaccine, Gardasil®, to prevent genital warts, in addition to its previous recommendation for females aged 9 to 26 years to prevent cervical cancer and genital warts. The marketing, expense, safety, and reactivity of Gardasil® continue to be the subject of controversy. Of the > 100 types of HPVs, approximately 40 are sexually transmitted, and HPV is the most common sexually transmitted disease. By age 50 years, 80% of women will have contracted a sexually transmitted HPV infection. While most individuals are clear of infection by 2 years, some types of HPV carry a high risk for progressing to cancer, and HPV is identifi ed in > 99% of patients with cervical cancer. Each year in the United States approximately 12 000 women develop cervical cancer and nearly 4000 die of it. Human papillomavirus is also associated with genital warts and other anogenital cancers. The United States has now licensed 2 vaccines against HPV, Gardasil® and Cervarix®. Gardasil® has been shown to be safe and effective in preventing HPV infections by types 6, 11, 16, and 18; types 16 and 18 are associated with 2 high-risk types of cervical cancer and are associated with 70% of all cervical cancers. Types 6 and 11 are associated with 90% of anogenital warts. Cervarix® has also been shown to be safe and effective in preventing HPV infections by types 16 and 18, but offers no known protection against anogenital warts.

Original languageEnglish (US)
Pages (from-to)121-129
Number of pages9
JournalPostgraduate Medicine
Volume122
Issue number2
DOIs
StatePublished - Mar 2010

Fingerprint

Uterine Cervical Neoplasms
Vaccination
Epidemiology
Condylomata Acuminata
Papillomavirus Infections
Warts
Advisory Committees
Immunization
Vaccines
Human papillomavirus 6
Papillomavirus Vaccines
Human papillomavirus 18
Human papillomavirus 16
Sexually Transmitted Diseases
Marketing
Neoplasms
Physicians
Safety
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Infection

Keywords

  • Condylomata acuminata
  • Human papillomavirus
  • Papillomaviridae
  • Papillomavirus infections
  • Uterine cervical neoplasms
  • Vaccines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus. / Broomall, Eileen M.; Reynolds, Sonya M.; Jacobson, Robert M.

In: Postgraduate Medicine, Vol. 122, No. 2, 03.2010, p. 121-129.

Research output: Contribution to journalArticle

Broomall, Eileen M. ; Reynolds, Sonya M. ; Jacobson, Robert M. / Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus. In: Postgraduate Medicine. 2010 ; Vol. 122, No. 2. pp. 121-129.
@article{3a9bbbf0fa494a10b27e2134474798d8,
title = "Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus",
abstract = "In October 2009, the Advisory Committee on Immunization Practices (ACIP) approved a newly licensed vaccine, Cervarix{\circledR}, directed against human papillomavirus (HPV) to prevent cervical cancer. The ACIP also expanded its recommendations against HPV by giving permission to physicians to vaccinate males aged 9 to 26 years with the previously licensed vaccine, Gardasil{\circledR}, to prevent genital warts, in addition to its previous recommendation for females aged 9 to 26 years to prevent cervical cancer and genital warts. The marketing, expense, safety, and reactivity of Gardasil{\circledR} continue to be the subject of controversy. Of the > 100 types of HPVs, approximately 40 are sexually transmitted, and HPV is the most common sexually transmitted disease. By age 50 years, 80{\%} of women will have contracted a sexually transmitted HPV infection. While most individuals are clear of infection by 2 years, some types of HPV carry a high risk for progressing to cancer, and HPV is identifi ed in > 99{\%} of patients with cervical cancer. Each year in the United States approximately 12 000 women develop cervical cancer and nearly 4000 die of it. Human papillomavirus is also associated with genital warts and other anogenital cancers. The United States has now licensed 2 vaccines against HPV, Gardasil{\circledR} and Cervarix{\circledR}. Gardasil{\circledR} has been shown to be safe and effective in preventing HPV infections by types 6, 11, 16, and 18; types 16 and 18 are associated with 2 high-risk types of cervical cancer and are associated with 70{\%} of all cervical cancers. Types 6 and 11 are associated with 90{\%} of anogenital warts. Cervarix{\circledR} has also been shown to be safe and effective in preventing HPV infections by types 16 and 18, but offers no known protection against anogenital warts.",
keywords = "Condylomata acuminata, Human papillomavirus, Papillomaviridae, Papillomavirus infections, Uterine cervical neoplasms, Vaccines",
author = "Broomall, {Eileen M.} and Reynolds, {Sonya M.} and Jacobson, {Robert M.}",
year = "2010",
month = "3",
doi = "10.3810/pgm.2010.03.2129",
language = "English (US)",
volume = "122",
pages = "121--129",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "2",

}

TY - JOUR

T1 - Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus

AU - Broomall, Eileen M.

AU - Reynolds, Sonya M.

AU - Jacobson, Robert M.

PY - 2010/3

Y1 - 2010/3

N2 - In October 2009, the Advisory Committee on Immunization Practices (ACIP) approved a newly licensed vaccine, Cervarix®, directed against human papillomavirus (HPV) to prevent cervical cancer. The ACIP also expanded its recommendations against HPV by giving permission to physicians to vaccinate males aged 9 to 26 years with the previously licensed vaccine, Gardasil®, to prevent genital warts, in addition to its previous recommendation for females aged 9 to 26 years to prevent cervical cancer and genital warts. The marketing, expense, safety, and reactivity of Gardasil® continue to be the subject of controversy. Of the > 100 types of HPVs, approximately 40 are sexually transmitted, and HPV is the most common sexually transmitted disease. By age 50 years, 80% of women will have contracted a sexually transmitted HPV infection. While most individuals are clear of infection by 2 years, some types of HPV carry a high risk for progressing to cancer, and HPV is identifi ed in > 99% of patients with cervical cancer. Each year in the United States approximately 12 000 women develop cervical cancer and nearly 4000 die of it. Human papillomavirus is also associated with genital warts and other anogenital cancers. The United States has now licensed 2 vaccines against HPV, Gardasil® and Cervarix®. Gardasil® has been shown to be safe and effective in preventing HPV infections by types 6, 11, 16, and 18; types 16 and 18 are associated with 2 high-risk types of cervical cancer and are associated with 70% of all cervical cancers. Types 6 and 11 are associated with 90% of anogenital warts. Cervarix® has also been shown to be safe and effective in preventing HPV infections by types 16 and 18, but offers no known protection against anogenital warts.

AB - In October 2009, the Advisory Committee on Immunization Practices (ACIP) approved a newly licensed vaccine, Cervarix®, directed against human papillomavirus (HPV) to prevent cervical cancer. The ACIP also expanded its recommendations against HPV by giving permission to physicians to vaccinate males aged 9 to 26 years with the previously licensed vaccine, Gardasil®, to prevent genital warts, in addition to its previous recommendation for females aged 9 to 26 years to prevent cervical cancer and genital warts. The marketing, expense, safety, and reactivity of Gardasil® continue to be the subject of controversy. Of the > 100 types of HPVs, approximately 40 are sexually transmitted, and HPV is the most common sexually transmitted disease. By age 50 years, 80% of women will have contracted a sexually transmitted HPV infection. While most individuals are clear of infection by 2 years, some types of HPV carry a high risk for progressing to cancer, and HPV is identifi ed in > 99% of patients with cervical cancer. Each year in the United States approximately 12 000 women develop cervical cancer and nearly 4000 die of it. Human papillomavirus is also associated with genital warts and other anogenital cancers. The United States has now licensed 2 vaccines against HPV, Gardasil® and Cervarix®. Gardasil® has been shown to be safe and effective in preventing HPV infections by types 6, 11, 16, and 18; types 16 and 18 are associated with 2 high-risk types of cervical cancer and are associated with 70% of all cervical cancers. Types 6 and 11 are associated with 90% of anogenital warts. Cervarix® has also been shown to be safe and effective in preventing HPV infections by types 16 and 18, but offers no known protection against anogenital warts.

KW - Condylomata acuminata

KW - Human papillomavirus

KW - Papillomaviridae

KW - Papillomavirus infections

KW - Uterine cervical neoplasms

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=77950351432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950351432&partnerID=8YFLogxK

U2 - 10.3810/pgm.2010.03.2129

DO - 10.3810/pgm.2010.03.2129

M3 - Article

C2 - 20203463

AN - SCOPUS:77950351432

VL - 122

SP - 121

EP - 129

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 2

ER -